Nasdaq · Healthcare
Cartesian Therapeutics, Inc. (RNAC)
As-reported financials and recent SEC filings for Cartesian Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$2.8M
Net income
$-130.3M
Net margin
—
Diluted EPS
$-5.02
ROE
103.2%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.8M | $38.3M | $26.0M | $110.8M | $85.1M |
| Gross profit | — | — | — | — | — |
| Operating income | $-143.4M | $-43.9M | $-86.4M | $14.5M | $-4.6M |
| Net income | $-130.3M | $-77.4M | $-219.7M | $35.4M | $-25.7M |
| Diluted EPS | $-5.02 | $-4.49 | $-16.59 | $0.93 | $-2.05 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-17
View on EDGAR →1442026-06-09
View on EDGAR →8-K2026-06-09
View on EDGAR →1442026-06-02
View on EDGAR →8-K2026-05-26
View on EDGAR →SCHEDULE 13G/A2026-05-06
View on EDGAR →S-82026-04-30
View on EDGAR →10-Q2026-04-30
View on EDGAR →Largest Healthcare peers
Go deeper on RNAC
Search Cartesian Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.